Strategic expansion Recent U.S. expansion and growing commercial team signals increased demand for micro-ultrasound systems; target hospital networks, urology groups, and regional distributors with an emphasis on prostate cancer diagnostic workflows.

Financial momentum Series of $10M financing rounds and ongoing funding indicate strong capital availability to support market penetration, product development, and expanded sales efforts in new regions.

Regulatory readiness CE Mark, FDA 510(k), and Health Canada licenses across ExactVu and FusionVu position the company well for cross‑border sales; leverage in multinational hospital chains and urology centers.

Clinical workflow fit High resolution micro‑US integrated with existing urology workflows offers a compelling value proposition for targeted biopsies and MRI fusion; opportunities in prostate cancer screening programs and guidance for MRI‑negative biopsy cases.

Growth drivers Proven leadership in micro‑ultrasound with regulatory approvals and customer demand cited by press; pursue partnerships with distributors, academic centers, and health systems expanding prostate cancer imaging portfolios.